EntreMed Announces FDA Acceptance Of IND Application For Panzem(R) In Rheumatoid Arthritis
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for Panzem(R) (2-Methoxyestradiol or 2ME2) in rheumatoid arthritis (RA). [click link for full article]

Reviewers AGREE On Osteoarthritis Of The Knee
Concerns over the cardiovascular safety of non-steroidal anti-inflammatory drugs (NSAIDs) led to the publication of several sets of fresh guidelines on the treatment of knee osteoarthritis. But a review of these guidelines, published in the online open access journal, Arthritis Research & Therapy, found many differences in treatments addressed and a lack of educational information in most of the articles. [click link for full article]

Acologix Presents Preclinical Data On Cartilage Regeneration By AC-100 At The OARSI 2007 World Congress On Osteoarthritis
Acologix, Inc., a privately held biopharmaceutical company, announced preclinical study results demonstrating that AC-100, its novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells, promoted cartilage regeneration in an animal model. The data was presented by Dr. [click link for full article]